Market Overview

Cytori Therapeutics Q4 Earnings Preview

Share:
Related CYTX
The Daily Biotech Pulse: Johnson & Johnson's Generic Unit Files NDA For Urinary Tract Cancer Drug, G1 Therapeutics Prices Offering
The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results

On Thursday, Cytori Therapeutics (NASDAQ: CYTX) will release its latest earnings report. Here is Benzinga's outlook for the company.

Earnings and Revenue

Wall Street expects EPS loss of 6 cents and sales around $2.74 million.

Cytori Therapeutics' loss in the same period a year ago was 24 cents. Quarterly sales came in at $1.46 million. If the company were to match the consensus estimate when it reports Thursday, sales would be up 86.9 percent from the year-ago period.

Cytori Therapeutics's reported EPS has stacked up against analyst estimates in the past like this:

 

Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate -0.13 -0.21 -0.28 -0.23
EPS Actual -0.14 -0.19 -0.26 -0.24

 

Stock Performance

Over the last 52-week period, shares are down 79.49 percent. Given that these returns are generally negative, long-term shareholders won't be happy going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.

Over the past 90 days, analysts have adjusted their estimates higher for EPS and revenues. The popular rating by analysts on Cytori Therapeutics stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Conference Call

Don't be surprised to see the stock move on comments made during its conference call. Cytori Therapeutics's Q4 conference call is scheduled to begin at 5:00 p.m. ET and can be accessed here.

Posted-In: Earnings News Previews Trading Ideas

 

Related Articles (CYTX)

View Comments and Join the Discussion!

Microchip Technology's 'Reasonable Valuation' Prompts Goldman Sachs Upgrade

Benzinga's Top Upgrades, Downgrades For March 8, 2018